Our study indicates that the hepatoprotective effects on NASH by rosiglitazone may at least partly be mediated by adipokines, since plasma leptin and TNFα levels were reduced and plasma adiponectin levels were increased. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatohepatitis.